128 related articles for article (PubMed ID: 7863274)
1. Clinical value of measuring soluble interleukin-2 receptor in polymyalgia rheumatica.
Gripenberg M; Franzén P; Fröseth B
Scand J Rheumatol; 1995; 24(1):26-8. PubMed ID: 7863274
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin 2 receptors in polymyalgia rheumatica/giant cell arteritis. Clinical and laboratory correlations.
Salvarani C; Macchioni P; Boiardi L; Rossi F; Casadei Maldini M; Mancini R; Beltrandi E; Spacca C; Lodi L; Portioli I
J Rheumatol; 1992 Jul; 19(7):1100-6. PubMed ID: 1512765
[TBL] [Abstract][Full Text] [Related]
3. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.
Salvarani C; Boiardi L; Macchioni P; Rossi F; Tartoni P; Casadei Maldini M; Mancini R; Beltrandi E; Portioli I
Ann Rheum Dis; 1995 Aug; 54(8):640-4. PubMed ID: 7677440
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble CD4 and CD8 levels in polymyalgia rheumatica.
Salvarani C; Boiardi L; Macchioni P; Casadei Maldini M; Mancini R; Beltrandi E; Rossi F; Portioli I
J Rheumatol; 1994 Oct; 21(10):1865-9. PubMed ID: 7837152
[TBL] [Abstract][Full Text] [Related]
5. Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6.
Cutolo M; Straub RH; Foppiani L; Prete C; Pulsatelli L; Sulli A; Boiardi L; Macchioni P; Giusti M; Pizzorni C; Seriolo B; Salvarani C
J Rheumatol; 2002 Apr; 29(4):748-56. PubMed ID: 11950017
[TBL] [Abstract][Full Text] [Related]
6. In polymyalgia rheumatica serum prolactin is positively correlated with the number of typical symptoms but not with typical inflammatory markers.
Straub RH; Georgi J; Helmke K; Vaith P; Lang B
Rheumatology (Oxford); 2002 Apr; 41(4):423-9. PubMed ID: 11961173
[TBL] [Abstract][Full Text] [Related]
7. Cytokines and adhesion molecules in patients with polymyalgia rheumatica.
Uddhammar A; Sundqvist KG; Ellis B; Rantapää-Dahlqvist S
Br J Rheumatol; 1998 Jul; 37(7):766-9. PubMed ID: 9714354
[TBL] [Abstract][Full Text] [Related]
8. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica.
Dolan AL; Moniz C; Dasgupta B; Li F; Mackintosh C; Todd P; Corrigall V; Panayi GS
Arthritis Rheum; 1997 Nov; 40(11):2022-9. PubMed ID: 9365092
[TBL] [Abstract][Full Text] [Related]
9. Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica.
Salvarani C; Boiardi L; Timms JM; Silvestri T; Ranzi A; Macchioni PL; Pulsatelli L; di Giovine FS
Clin Exp Rheumatol; 2000; 18(5):591-5. PubMed ID: 11072599
[TBL] [Abstract][Full Text] [Related]
10. Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica.
van der Geest KS; Abdulahad WH; Chalan P; Rutgers A; Horst G; Huitema MG; Roffel MP; Roozendaal C; Kluin PM; Bos NA; Boots AM; Brouwer E
Arthritis Rheumatol; 2014 Jul; 66(7):1927-38. PubMed ID: 24623536
[TBL] [Abstract][Full Text] [Related]
11. Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.
van der Geest KS; Abdulahad WH; Rutgers A; Horst G; Bijzet J; Arends S; Roffel MP; Boots AM; Brouwer E
Rheumatology (Oxford); 2015 Aug; 54(8):1397-402. PubMed ID: 25724206
[TBL] [Abstract][Full Text] [Related]
12. Circulating RANKL/OPG in polymyalgia rheumatica.
Pulsatelli L; Dolzani P; Silvestri T; Boiardi L; Salvarani C; Macchioni P; Facchini A; Meliconi R
Clin Exp Rheumatol; 2007; 25(4):621-3. PubMed ID: 17888221
[TBL] [Abstract][Full Text] [Related]
13. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk.
Pulsatelli L; Boiardi L; Pignotti E; Dolzani P; Silvestri T; Macchioni P; Cantini F; Salvarani C; Facchini A; Meliconi R
Arthritis Rheum; 2008 Aug; 59(8):1147-54. PubMed ID: 18668607
[TBL] [Abstract][Full Text] [Related]
14. EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).
Leeb BF; Bird HA; Nesher G; Andel I; Hueber W; Logar D; Montecucco CM; Rovensky J; Sautner J; Sonnenblick M
Ann Rheum Dis; 2003 Dec; 62(12):1189-94. PubMed ID: 14644857
[TBL] [Abstract][Full Text] [Related]
15. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis.
Lundberg I; Hedfors E
J Rheumatol; 1990 Oct; 17(10):1340-5. PubMed ID: 2254893
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica.
Pulsatelli L; Peri G; Macchioni P; Boiardi L; Salvarani C; Cantini F; Mantovani A; Meliconi R
Clin Exp Rheumatol; 2010; 28(5):756-8. PubMed ID: 20822713
[TBL] [Abstract][Full Text] [Related]
17. Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica.
Boiardi L; Casali B; Farnetti E; Pipitone N; Nicoli D; Cantini F; Macchioni P; Bajocchi G; Catanoso MG; Pulsatelli L; Consonni D; Salvarani C
J Rheumatol; 2006 Apr; 33(4):703-8. PubMed ID: 16583473
[TBL] [Abstract][Full Text] [Related]
18. The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica.
Straub RH; Glück T; Cutolo M; Georgi J; Helmke K; Schölmerich J; Vaith P; Lang B
Rheumatology (Oxford); 2000 Jun; 39(6):624-31. PubMed ID: 10888707
[TBL] [Abstract][Full Text] [Related]
19. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study.
Catanoso MG; Macchioni P; Boiardi L; Pipitone N; Salvarani C
Arthritis Rheum; 2007 Dec; 57(8):1514-9. PubMed ID: 18050171
[TBL] [Abstract][Full Text] [Related]
20. [Rheumatic polymyalgia and temporal arteritis. Case contribution and bibliographic review].
Manganelli P; Mercadanti M; Nervetti A; Ambanelli U
Minerva Med; 1987 Mar; 78(5):287-96. PubMed ID: 3822219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
